Immuno-Oncology Antibodies
Total Trials
4
As Lead Sponsor
As Collaborator
0
Total Enrollment
100
NCT06037018
Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies
Phase: Phase 1
Role: Lead Sponsor
Start: Aug 7, 2023
Completion: Mar 31, 2026
NCT06888960
Safety Study of CC312 in Autoimmune Disease Patients
Phase: Early Phase 1
Start: Nov 8, 2024
Completion: Nov 8, 2026
NCT07177911
Safety and Efficacy Study of CC312 for Moderate to Severe SLE
Start: Sep 11, 2025
Completion: Sep 10, 2027
NCT07193810
A Study of CC312 for Relapsed/Refractory Autoimmune Diseases
Start: Sep 30, 2025
Completion: Sep 29, 2027
Loading map...